A nonimaging catheter for measurement of coronary artery lumen area
Objectives: The objective of this human pilot study was to determine the safety and the level of agreement between a novel nonimaging 2.7 Fr. catheter‐based system (LumenRECON, LR) that uses electrical conductance for measurement of lumen cross‐sectional area (CSA) with intravascular ultrasound (IVU...
Saved in:
Published in | Catheterization and cardiovascular interventions Vol. 78; no. 2; pp. 202 - 210 |
---|---|
Main Authors | , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Hoboken
Wiley Subscription Services, Inc., A Wiley Company
01.08.2011
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Objectives: The objective of this human pilot study was to determine the safety and the level of agreement between a novel nonimaging 2.7 Fr. catheter‐based system (LumenRECON, LR) that uses electrical conductance for measurement of lumen cross‐sectional area (CSA) with intravascular ultrasound (IVUS) and quantitative coronary angiography (QCA). Based on previous animal studies, we hypothesized the level of agreement between LR and IVUS to be 13%. Background: Accurate and reproducible vessel sizing is essential for optimal percutaneous coronary intervention (PCI). Methods: A total of 12 patients were studied to evaluate the safety, accuracy, and reproducibility of the system in comparison with IVUS and QCA. The CSA of coronary arteries was determined by IVUS, QCA, and LR in the distal, proximal, and center of a lesion during standard PCI. Results: A Bland‐Altman plot of the LR versus IVUS and QCA show a nonsignificant mean difference between the two measurements of 0.04 and 0.07 mm in diameter, respectively. The root mean square error of LR versus IVUS and QCA was 14.3 and 25.8% of the mean IVUS or QCA diameter, respectively. The mean of the difference between two LR duplicate measurements was nearly zero (0.03 mm) and the repeatability coefficient was within 8.7% of the mean of the two measurements. There were no procedural complications nor were any device‐related MACE reported within 30 days of the procedure. Conclusions: This proof of concept pilot study establishes the safety and accuracy of the conductance technology for a pivotal trial of coronary sizing. © 2011 Wiley‐Liss, Inc. |
---|---|
Bibliography: | ark:/67375/WNG-L1GFLDG6-6 Conflict of interest: Dr. Hermiller is a member of FlowCo's Scientific Advisory Board (SAB) and has received a nominal equity interest in exchange for his services. Drs. Bigelow and Bhatt are non-paid members of flowco's SAB. Dr. Kassab is the founder of Flowco. All other coauthors have nothing to disclose in relation to this study. istex:4CE66065E8C7DC80EF92DBB96AAAEE71CF3B8D5E Flowco Inc ArticleID:CCD22842 Conflict of interest: Dr. Hermiller is a member of FlowCo's Scientific Advisory Board (SAB) and has received a nominal equity interest in exchange for his services. Drs. Bigelow and Bhatt are non‐paid members of flowco's SAB. Dr. Kassab is the founder of Flowco. All other coauthors have nothing to disclose in relation to this study. |
ISSN: | 1522-1946 1522-726X |
DOI: | 10.1002/ccd.22842 |